A Novel IGLC2 Gene Linked With Prognosis of Triple-Negative Breast Cancer

Yu Tien Chang, Wen Chiuan Tsai, Wei Zhi Lin, Chia Chao Wu, Jyh Cherng Yu, Vincent S. Tseng, Guo Shiou Liao*, Je Ming Hu, Huan Ming Hsu, Yu Jia Chang, Meng Chiung Lin, Chi Ming Chu, Chien Yi Yang

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: Immunoglobulin-related genes are associated with the favorable prognosis of triple-negative breast cancer (TNBC) patients. We aimed to analyze the function and prognostic value of immunoglobulin lambda constant 2 (IGLC2) in TNBC patients. Methods: We knocked down the gene expression of IGLC2 (IGLC2-KD) in MDA-MB-231 cells to evaluate the proliferation, migration, and invasion of tumors via 3-(4,5-Dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay, wound healing, and transwell cell migration assay respectively. Relapse-free survival (RFS) and distant metastasis-free survival (DMFS) analyses were conducted using the KM plotter online tool. The GSE76275 data set was used to analyze the association of IGLC2 and clinical characteristics. A pathway enrichment analysis was conducted using the next-generation sequencing data of wild-type and IGLC2-KD MDA-MB-231 cells. Results: The low gene expression of IGLC2 was related to unfavorable RFS, DMFS. The high expression of IGLC2 was exhibited in the basal-like immune-activated (BLIA) TNBC molecular subtype, which was immune-activated and showed excellent response to immune therapy. IGLC2 was positively correlated with programmed death-ligand 1 (PD-L1) as shown by Spearman correlation (r = 0.25, p < 0.0001). IGLC2 had a strong prognostic effect on lymph node-negative TNBC (RFS range: 0.31, q value= 8.2e-05; DMFS = 0.16, q value = 8.2e-05) but had no significance on lymph node-positive ones. The shRNA-mediated silencing of IGLC2 increased the proliferation, migration, and invasion of MDA-MB-231 cells. The results of pathway enrichment analysis showed that IGLC2 is related to the PI3K-Akt signaling pathway, MAPK signaling pathway, and extracellular matrix–receptor interaction. We confirmed that MDA-MB-231 tumor cells expressed IGLC2, subverting the traditional finding of generation by immune cells. Conclusions: IGLC2 linked with the proliferation, migration, and invasion of MDA-MB-231 cells. A high expression of IGLC2 was related to favorable prognosis for TNBC patients. IGLC2 may serve as a biomarker for the identification of TNBC patients who can benefit the most from immune checkpoint blockade treatment.

Original languageEnglish
Article number759952
JournalFrontiers in Oncology
StatePublished - 27 Jan 2022


  • MDA-MB-231
  • breast cancer
  • distant metastasis-free survival
  • immunoglobulin
  • next-generation sequencing
  • prognosis
  • relapse-free survival
  • triple-negative breast cancer (TNBC)


Dive into the research topics of 'A Novel IGLC2 Gene Linked With Prognosis of Triple-Negative Breast Cancer'. Together they form a unique fingerprint.

Cite this